Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804661 | 0.86 | HRH4 (0.56) | SMN1; SMN2HRH4HRH3MEN1KMT2A | |
| SCHEMBL14818977 | 0.82 | MEN1 (0.58) | SMN1; SMN2HRH4HRH3GPR68MEN1 | |
| SCHEMBL12069796 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2HRH4MEN1KMT2APTGS2 | |
| SCHEMBL14804660 | 0.78 | MAP2K7 (0.43) | PIM1DYRK1ACLK4 | |
| SCHEMBL12268319 | 0.74 | HRH4 (0.44) | HRH4HTR1BHTR2BGPR65HRH3 | |
| SCHEMBL14804484 | 0.72 | PTGS2 (0.37) | MEN1KMT2APTGS2 | |
| SCHEMBL14804485 | 0.68 | CYP1A2 (0.43) | SMN1; SMN2MEN1KMT2ACLK4 | |
| SCHEMBL20919214 | 0.68 | NUDT1 (0.52) | HRH4HRH3 | |
| SCHEMBL14818974 | 0.68 | MEN1 (0.60) | SMN1; SMN2HRH4HRH3MEN1KMT2A | |
| SCHEMBL15417803 | 0.68 | AURKA (0.45) | MEN1KMT2ADYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | PDPK1, PDK1, PDK3 | SMN1; SMN2 3875/4885HRH4 1463/4885HTR1B 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.